Evotec SE (EVO)

NasdaqGS: EVO · Real-Time Price · USD

1.90

+0.10 (5.56%)

At close: Sep 02, 2026, 3:58 PM

1.90

+0.00%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

5.56% (1D)

Bid	1.37
Market Cap	675M
Revenue (ttm)	717M
Net Income (ttm)	-197M
	1.26
	-0.68
	n/a
	-10
P/B (ttm)	0.87
P/S (ttm)	0.94
Earnings Date	Nov 5, 2026

Ask	2.44
Volume	48,222
Avg. Volume (20D)	54,184
Open	1.88
Previous Close	1.80
Day's Range	1.88 - 1.93
52-Week Range	1.80 - 4.27
Analyst	n/a
Price Target	3.21 (68.95%)
Dividends	n/a
Ex-Dividend Date	n/a

About EVO

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibroti...

Sector Healthcare

IPO Date Feb 5, 2004

Employees 4,461

Stock Exchange NasdaqGS

Ticker Symbol EVO

Website https://www.evotec.com

Full Company Profile

Financial Performance

In 2025, Evotec SE's revenue was 788.37M, a decrease of -1.08% compared to the previous year's 796.97M. Earnings were -103.52M, a decrease of -47.21%.

Financial Statements

Analyst Forecast

According to 4 analyst ratings, the average rating for EVO stock is "null". The 12-month stock price forecast is 3.21, which is upside of 68.95% from the latest price.

Stock Forecasts

Earnings Surprise

Evotec SE has released their quarterly earnings on Aug 12, 2026:

Revenue of $156.64M misses estimates by $0, with -21.67% YoY decline.
EPS of -0.13 misses estimates by -0.09, with -8.33% YoY decline.

Next Earnings Release

Evotec SE is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

3 weeks ago · Simply Wall St.

Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention

Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger net loss alongside a sharp change in r...

3 weeks ago · Pharmaceutical Technology

Evotec and Odyssey collaborate on AI-enabled R&D

The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.

1 month ago · The Wall Street Journal

Health Care Roundup: Market Talk

Find insight on Hikma Pharmaceuticals, Evotec and more in the latest Market Talks covering health care.

1 month ago · GuruFocus.com

Evotec SE (EVO) Q2 2026 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...

Despite a challenging quarter with revenue declines, Evotec SE (EVO) focuses on liquidity growth, strategic partnerships, and cost-saving initiatives to drive future success.

1 month ago · MarketBeat

Evotec Q2 Earnings Call Highlights

Evotec (NASDAQ:EVO) reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower convers...

Page 1 of 2